Marina Riggio
B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Journal: Oncotarget
Published: May 20, 2025
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.
Journal: Scientific reports
Published: November 13, 2022
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
Journal: International journal of cancer
Published: September 03, 2021
Molecular mechanisms underlying AMH elevation in hyperoestrogenic states in males.
Journal: Scientific reports
Published: June 30, 2020
FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
Journal: International journal of cancer
Published: September 18, 2018
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.
Journal: Scientific reports
Published: November 11, 2016
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
Journal: International journal of cancer
Published: February 05, 2014
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Journal: Carcinogenesis
Published: December 20, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026